http://dx.doi.org/10.5772/55223

evidences suggest that autophagy has up-regulated for the degeneration of misfolded proteins and usually is neuroprotective in those disorders.




**Figure 4.** Pathologic findings in myopathies with rimmed vacuoles. Clinically and etiologically different disorders are showing same pathologic features (RVs; arrows) in skeletal muscles. HE-hematoxylin and eosin; mGT-modified Gomori trichrome; IBM-inclusion body myositis; MFM-myofibrillar myopathy; IBMPFD-inclusion body myopathy with Paget's disease of bone and frontotemporal dementia; MSS-Marinesco-Sjögren syndrome.

## 3. GNE myopathy

GNE myopathy is one of the well described rimmed vacuolar myopathies. It is an autosomal recessive myopathy originally reported in 1981 by Nonaka et al. [43, 44], and thus is also referred as distal myopathy with rimmed vacuoles (DMRV) or Nonaka myopathy. In 1984, Argov and Yarom [45] reported a similar disorder among Iranian Jews with the title of 'rimmed vacuolar myopathy sparing quadriceps'. And the term 'quadriceps sparing myopathy' and 'hereditary inclusion body myopathy (hIBM)' has also been used to refer this disease. Since these two disorders are thought to be identical and caused by GNE mutations [46], it would be better to harmonized the naming of this disease. The experts have recently designated the disease to be called "GNE myopathy".

Among the AVMs secondarily caused by extra-lysosomal defects, GNE myopathy has some advantages for the pathomechanism research. It is a single gene disorder with a homogeneous phenotype and the model mice which evidently display similar features of a human GNE myopathy have been generated [47]. Regardless of the upstream causes, autophagy in myopathies is thought to be mainly attributed to abnormal lysosomal function regarding their effects on myofiber breakdown in common and RVs appreciated in various kinds of myopathies is known

to share similar histological and biochemical features. Thus, a comprehensive review of achievements and addressed issues in GNE myopathy research can broaden our understanding of this common pathomechanism of autophagy in rimmed vacuolar myopathies.

### 3.1. Clinical and pathologic features of GNE myopathy

Clinically, GNE myopathy is an early adult-onset progressive myopathy that affects the tibialis anterior muscle preferentially but spares quadriceps femoris muscles. The symptoms of distal limb muscle weakness start to affect the patient from the second or third decades, and most of the patients become wheelchair-bound between twenties and sixties with a median time to loss of ambulation of 17 years after disease onset [48]. Although the tibialis anterior muscle is most significantly affected, gastrocnemius, hamstrings, paraspinal, and sternocleidomastoid muscles are also involved from an early stage. Cardiac and respiratory muscles are less involved. Serum creatine kinase (CK) levels are normal to mildly elevated [49].

Muscle pathology (Figure 5) is characterized by the presence of RVs predominantly in atrophic fibers, which are occasionally aggregated and form small groups. These RVs are actually clusters of autophagic vacuoles and multi-lamellar bodies. They often contain congophilic amyloid material and deposits that are immunoreactive to β–amyloid and its precursor protein, ubiquitin, and tau protein. Ultrastructurally, the filamentous inclusions measuring 15-20 nm in diameter are seen in both cytoplasm and nucleus with the presence of autophagic vacuoles. Necrotic and regenerating fibers can be rarely seen in GNE myopathy [4, 43, 44, 49].




**Figure 5.** Pathologic findings in GNE myopathy. Rimmed vacuoles (arrows) are predominantly present in atrophic fibers. HE-hematoxylin and eosin; mGT-modified Gomori trichrome; Acid P-acid phoaphatase.

### 3.2. Molecular pathomechanism of GNE myopathy

GNE myopathy is caused by mutations in the gene encoding a key enzyme in sialic acid biosynthesis, UDP-*N*-acetylglucosamine 2-epimerase/*N*-acetylmannosamine kinase (GNE) [50]. Previous studies have shown that predominant *GNE* mutations exist in certain populations, such as

the V572L mutation in Japanese patients and the M712T mutation in Middle Eastern Jews [46, 50-52]. But it is now evident that GNE myopathy is not restricted to people of Japanese and Jewish ancestry, but they are widely distributed throughout all ethnic groups [53-56]. Recent study showed that homozygosity for V572L (the most common mutation in Japanese population) resulted in more severe phenotypes with earlier symptom onset and faster disease progression, implying the existence of genotype/phenotype correlation in GNE myopathy [48].

After the identification of *GNE* mutations, we found that GNE enzymatic activity measured *in vitro* in cells transfected with mutated *GNE* constructs is decreased. And we demonstrated that the levels of sialic acid in primary cultured cells from GNE myopathy patients are reduced and can be corrected by the addition of free sialic acid [57]. But the mechanism how the hyposialylation makes the pathognomonic pathologic change in skeletal muscle of GNE myopathy has still remained unknown. To answer the question, we developed a model mouse for GNE myopathy.

## 4. Animal model: A *Gne* knock out mouse expressing human *GNE* D176V mutation

Since the null mutation in *GNE* is known to be embryonically lethal [58], we adopted a different strategy to generate $Gne^{-/-}$hGNED176VTg, a mouse model for GNE myopathy [47, 59]. Our model harbored a transgene of D176V mutated human *GNE* (one of the most prevalent mutations among Japanese GNE myopathy patients) but is knocked-out of endogenous *GNE*, resulted in that only mutated GNE proteins were highly expressed and the endogenous one was disrupted. These mice exhibited marked hyposialylation in serum, muscle and other organs and reproduced similar myopathic phenotypes seen in the skeletal muscles of human GNE myopathy patients.

The muscle weakness, decreased whole muscle mass and reduced contractile power appeared in an age-related manner [60]. After 20 weeks of age, the GNE myopathy mice started to show physiologic muscle weakness, observed as impaired motor performance and reduced force generation of the skeletal muscle. This reduction of the force might be attributed to muscle atrophy, as specific twitch and tetanic forces per cross-section area are maintained at this age. The reduction in gross size of the skeletal muscle is accompanied by an increase in the number of small angular fibers. After 30 weeks of age, specific force generation in the gastrocnemius and tibialis anterior muscles was notably reduced, while myofiber size variation became more remarkable. Intracellular deposition of amyloid and other various proteins was appreciated in the gastrocnemius muscle at this age. After 40 weeks, the muscle force generation worsened, as reflected by increased twitch/tetanic ratio, which might be due to the appearance of the characteristic RV and accumulation of autophagic vacuoles [61]. With these results, the $GNE^{-/-}$ hGNED176VTg mouse is the only existing pathogenic model for GNE myopathy up to date.

Muscle pathology of GNE myopathy mice reveals RVs after 40 weeks of age (Figure 6). Intense acid phosphatase staining and expression of lysosomal-associated membrane proteins (LAMPs) and LC3 imply that autophagic process is activated in skeletal muscles of the model mice [47]. Inclusion bodies are also appreciated with expression of various protein markers.




**Figure 6.** Pathologic findings in the GNE myopathy model mouse. (A) Hematoxylin and eosin sections showing fibers with RVs and cytoplasmic inclusions. (B) modified Gomori trichrome; (C) Acid phosphatase; (D) Congo red. Immunoreactivity to lysosomal proteins confirm the presence of autophagy in fibers with RVs. (E) LAMP-1; (F) LAMP-2; (G) LC3. Intracellular deposition of amyloid is seen in vacuolated or nonvacuolated fibers. (H) BACE2; (I) AβPP; (J) β-amyloid 1-42; (K) β -amyloid 1-40; (L) β -amyloid oligomeric. Neurofilament deposition is observed in the myofibers. (M) SM-31; (N) SM-310. (O) phosphorylated tau; (P) ubiquitin; (Q) Grp94. Sarcolemmal proteins are deposited within the vicinity of RVs. (R) α-dystroglycan (S) β-dystroglycan (T) α-sarcoglycan. Bar-20μm. (Reproduced from [47])

http://dx.doi.org/10.5772/55223

### 4.1. Autophagy in a mouse model of GNE myopathy

The characteristic RVs are observed after 40 weeks in the GNE myopathy model mouse. Like human muscle pathologic findings, these vacuoles have high acid phosphatase activity and strongly stained by various lysosomal antibodies (Figure 6) [47]. Ultrastructurally, the RVs contain multi-lamellar bodies, electron-dense bodies, and heterogeneous cytoplasmic debris which are surrounded by double membranes, indicating these are autophagic vacuoles (Figure 7). In the near areas, several vacuoles have a single limiting membrane and some cellular debris have no membrane, indicating degradated or ruptured vacuoles. Interestingly, filamentous or granular deposits considered as amyloid often appear with the autophagic vacuoles. And these probable amyloid deposits are also observed in the normal areas, which may suggest that the deposition of protein precede the accumulation of autophagic vacuoles [61].



**Figure 7.** Electron microscopy findings in the GNE myopathy mouse model. Various cellular debris are enclosed by nacent (arrows) and degenerative (double arrows) autophagic vacuoles. Large osmiophilic doposits (asterisk) can be also seen. Dense ovoid bodies (double asterisk) are seen with autophagic vacuoles (double arrowheads) suggesting that these deposits predate RVs formation. Bars-1μm. (Reproduced from [61])

## 5. Prophylactic treatment with sialic acid metabolites in the GNE myopathy model mice

A possibility of the development of therapy for GNE myopathy was demonstrated in our model mice. As the addition of sialic acid metabolites has been shown to recover overall

hyposialylation in cells [57], we have challenged in administering sialic acid compounds *in vivo*. We administered 2-epimerase/N-acetylmannosamine (ManNAc) to the GNE myopathy model mice from the preclinical age (5~6 weeks) continuously until the mice reached the age when all myopathic symptoms appear (54~57 weeks). ManNAc was added to drinking water and given in three doses: 20mg (low dose), 200mg (medium dose), and 2000mg (high dose)/kg body weight of mice in a day. During the treatment period, survival rate was remarkably improved as compared with control-treated mice at all three doses (Figure 8). At the end of the treatment, the phenotypes of the mice were evaluated and compared with placebo group and non-affected littermates. At all doses, motor performance and physiological contractile properties of skeletal muscles were remarkably improved. Sialic acid levels in the blood and tissues were elevated, and more importantly, the levels of sialic acid in the muscle were recovered to an almost normal level after treatment, providing evidence that prophylactic oral administration of ManNAc to the the model mice was notably effective. Then we also examined the effect of oral *N*-acetylneuraminic acid (NeuAc) and sialyllactose together with minimum dose of ManNAc (20 mg/kg bodyweight/day) on GNE myopathy mice starting at the preclinical age of 10~20 weeks. Treatment was also continued up to 54~57 weeks of age and similar beneficial effects on motor performance and force generation of skeletal muscles were obtained [62].




**Figure 8.** Favorable effects of sialic acid metabolites administration in GNE myopathy model mice. Survival curves (left upper), treadmill performance test (right upper), and contractile properties of specific isometric force ($P_t$/CSA; left lower) and specific tetanic force ($P_o$/CSA; right lower). (Reproduced from [62])

Sialic acid metabolites administration also led to a marked change in the muscle pathology of GNE myopathy mice (Figure 9) [62]. Although all mice in the control-treated group showed

RVs in the gastrocnemius muscles, only a few in the treatment groups showed RVs. As RVs are autophagic in nature, we checked for acid phosphatase staining and found decreased staining. The expression of LC3 and Lamp2, which are markers for autophagosomal structures, were not observed in the muscle sections of ManNAc treated mice, except for one mouse that had few RVs in the muscle. The amounts of LC3-I and LC3-II, used as an index to analyze autophagic induction in tissues, were lower after treatment. Treatment also increased muscle cross-sectional area (CSA) and diminished congophilic, amyloid-positive and tau-positive inclusions.




**Figure 9.** Pathologic improvement after treatment with sialic acid metabolites in GNE myopathy model mice. (Reproduced from [62])

Our successful prophylactic treatment results on the model mice supports the current concept that hyposialylation is one of main factors contributing the pathogenesis of GNE myopathy. This concept suggests that GNE myopathy is a potentially treatable disease and A phase I clinical trial for human patients using oral sialic acid therapy is recently underway in Japan.

## 6. Future issue 1 — Hypothesized pathway from hyposialylation to RVs formation

Although it has been already demonstrated that hyposialylation is a key factor in the pathomechanism of GNE myopathy and sialic acid metabolites administration can prevent the development of myopathic phenotype in GNE myopathy model mouse, there still remains an unexplained link between hyposialylation due to GNE mutations and the pathognomonic findings in the muscle. However, since the the model mice exhibit hyposialylation and intracellular amyloid deposition before the characteristic RVs appear, we can appreciate that the dysfunctional autophagy is a downstream phenomenon to hyposialylation and amyloid deposition in GNE myopathy.

In normal macroautophgy process, cytoplasm and organelles are enclosed by an isolated membrane (phagophore) to form an autophagosome. The outer membrane of the autophago-

some fuses with the lysosome, and the internal material is degraded in the Autolysosome [63]. However, in hyposialylated condition, the autophagy does not progress normally. As hyposialylation can lead to abnormal protein configuration or misfolding, an excessive amount of misfolded glycoproteins which were not degraded in the ER may cause abnormal autophagy in GNE myopathy (Figure 10). Hyposialylation may also lead to abnormal protein processing which can induce abnormal protein deposits in cytoplasm. In addition, there are several reports that suggested oxidative stress is involved in the upstream pathways to amyloid deposition and/or RVs formation. One previous report showed that autophagic vacuoles were associated to be a site of amyloidogenic amyloid precursor protein processing and intra-lysosomal amyloid-β accumulation was induced by oxidative stress [64]. And another report demonstrated that reactive oxygen species may contribute to the formation of autophagosomes [65]. An experimental result implying a biologic function of sialic acid as an oxygen radical scavenger suggests hyposialylation can directly contribute to the increase of oxidative stress and support the above concept [66].




**Figure 10.** Hypothesized mechanism of dysfunctional autophagy in GNE myopathy.

## 7. Future issue 2 — The common molecular processes underlying autophagic vacuoles formation in rimmed vacuolar myopathies

Regarding the pathomechanism of rimmed vacuolar myopathies, it is interesting to figure out how various kinds of myopathies from different etiologies can share the similar pathology and

undergo similar pathogenic process. One of the most impressive finding is that the accumulation of misfolded proteins and subsequent activation of autophagy are observed in all kinds of rimmed vacuolar myopathies commonly and constantly, which bring us that intra-myofiber accumulation of conformationally modified proteins plays a primary pathologic role in these disorders. However, up-regulation of autophagy alone may not be enough to form RVs if the pathways are operating properly. The primary role of autophagy is to protect cells under stress conditions and it is widely accepted that in most of neurodegenerative diseases, activation of autophagic process is an adaptive response against disease-related stress conditions. The fact that not all myofibrillar myopathy muscles show RVs suggests that the other pathways are necessary to complete RV formation.

Dysfunctional autophagy is another important common feature in rimmed vacuolar myopathies. It was already demonstrated that autophagy is impaired in sIBM, IBMPFD, GNE myopathy, and Marinesco-Sjögren syndrome [26, 37, 40, 61]. Regardless of upstream process, autophagosomes are proliferated and enlarged with lysosomal dysfunction and macroautophagy disregulation, and it might be contribute or worsen the abnormal accumulation of various proteins such as amyloids, p-tau, $\alpha$-synuclein, and p62. This two major common process, up-regulated and dysfunctional autophagy, possibly develop characteristic RVs in skeletal muscle pathology.




**Figure 11.** Hypothesized common mechanism of rimmed vacuoles formation in various AVMs.

## 8. Conclusion

Herein we presented the current knowledge on AVMs and recent approaches to the pathogenesis of rimmed vacuolar myopathies. With the model mice, we proved that hyposialylation is a key factor in the pathomechanism of GNE myopathy. And we also provided evidences

that prophylactic treatment with sialic acid metabolites prevents the myopathic phenotype and substantially reduced the number of RVs in the GNE myopathy mice. Since rimmed vacuolar myopathies have revealed to share common pathways regarding the autophagic vacuoles formation irrespective of heterogeneous clinical phenotype and etiology, our experimental achievement can broaden the general understanding on the common pathomechanism of AVMs.

## Acknowledgements

This work is supported by JSPS KAKENHI Grant Number 23390236, by Comprehensive Research on Disability Health and Welfare from the Ministry of Health and Labour, and by Intramural Research Grant (22-5) for Neurological and Psychiatric Disorders of NCNP.

## Author details

Anna Cho and Satoru Noguchi*

Department of Neuromuscular Research, National Institute of Neuroscience, NCNP, Tokyo, Japan

## References

[1] Wong, E, & Cuervo, A. M. Autophagy gone awry in neurodegenerative diseases. Nature neuroscience (2010). , 13(7), 805-811.

[2] Mizushima, N, Levine, B, Cuervo, A. M, & Klionsky, D. J. Autophagy fights disease through cellular self-digestion. Nature (2008). , 451(7182), 1069-1075.

[3] Winslow, A. R, & Rubinsztein, D. C. Autophagy in neurodegeneration and development. Biochimica et biophysica acta (2008). , 1782(12), 723-729.

[4] Nishino, I. Autophagic vacuolar myopathies. Current neurology and neuroscience reports (2003). , 3(1), 64-69.

[5] Nishino, I. Autophagic vacuolar myopathy. Seminars in pediatric neurology (2006). , 13(2), 90-95.

[6] Malicdan, M. C, & Nishino, I. Autophagy in lysosomal myopathies. Brain Pathol (2012). , 22(1), 82-88.

[7] Smith, J, Zellweger, H, & Afifi, A. K. Muscular form of glycogenosis, type II (Pompe). Neurology (1967). , 17(6), 537-549.

[8] Danon, M. J, & Oh, S. J. DiMauro S, Manaligod JR, Eastwood A, Naidu S, et al. Lysosomal glycogen storage disease with normal acid maltase. Neurology (1981). , 31(1), 51-57.

[9] Nishino, I, Fu, J, Tanji, K, Yamada, T, Shimojo, S, Koori, T, et al. Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease). Nature (2000). , 406(6798), 906-910.

[10] Kishnani, P. S, & Howell, R. R. Pompe disease in infants and children. The Journal of pediatrics (2004). Suppl) S, 35-43.

[11] Van Der Ploeg, A. T, & Reuser, A. J. Pompe's disease. Lancet (2008). , 372(9646), 1342-1353.

[12] van den Hout HM, Hop W, van Diggelen OP, Smeitink JA, Smit GP, Poll-The BT, et al. The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. Pediatrics (2003). , 112(2), 332-340.

[13] Van Der Beek, N. A, Hagemans, M. L, Van Der Ploeg, A. T, Reuser, A. J, & Van Doorn, P. A. Pompe disease (glycogen storage disease type II): clinical features and enzyme replacement therapy. Acta neurologica Belgica (2006). , 106(2), 82-86.

[14] Kishnani, P. S, Corzo, D, Nicolino, M, Byrne, B, Mandel, H, Hwu, W. L, et al. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology (2007). , 68(2), 99-109.

[15] Chen, L. R, Chen, C. A, Chiu, S. N, Chien, Y. H, Lee, N. C, Lin, M. T, et al. Reversal of cardiac dysfunction after enzyme replacement in patients with infantile-onset Pompe disease. The Journal of pediatrics (2009). e272., 155(2), 271-275.

[16] Winkel, L. P, Hagemans, M. L, Van Doorn, P. A, Loonen, M. C, Hop, W. J, Reuser, A. J, et al. The natural course of non-classic Pompe's disease; a review of 225 published cases. Journal of neurology (2005). , 252(8), 875-884.

[17] Kroos, M, Hoogeveen-westerveld, M, Michelakakis, H, Pomponio, R, Van Der Ploeg, A, Halley, D, et al. Update of the pompe disease mutation database with 60 novel GAA sequence variants and additional studies on the functional effect of 34 previously reported variants. Human mutation (2012). , 33(8), 1161-1165.

[18] Fukuda, T, Ewan, L, Bauer, M, Mattaliano, R. J, Zaal, K, Ralston, E, et al. Dysfunction of endocytic and autophagic pathways in a lysosomal storage disease. Annals of neurology (2006). , 59(4), 700-708.

[19] Sugie, K, Noguchi, S, Kozuka, Y, Arikawa-hirasawa, E, Tanaka, M, Yan, C, et al. Autophagic vacuoles with sarcolemmal features delineate Danon disease and related myopathies. Journal of neuropathology and experimental neurology (2005). , 64(6), 513-522.

[20] Kalimo, H, Savontaus, M. L, Lang, H, Paljarvi, L, Sonninen, V, Dean, P. B, et al. X-linked myopathy with excessive autophagy: a new hereditary muscle disease. Annals of neurology (1988). , 23(3), 258-265.

[21] Yamamoto, A, Morisawa, Y, Verloes, A, Murakami, N, Hirano, M, Nonaka, I, et al. Infantile autophagic vacuolar myopathy is distinct from Danon disease. Neurology (2001). , 57(5), 903-905.

[22] Yan, C, Tanaka, M, Sugie, K, Nobutoki, T, Woo, M, Murase, N, et al. A new congenital form of X-linked autophagic vacuolar myopathy. Neurology (2005). , 65(7), 1132-1134.

[23] Amato, A. A, & Barohn, R. J. Inclusion body myositis: old and new concepts. Journal of neurology, neurosurgery, and psychiatry (2009). , 80(11), 1186-1193.

[24] Griggs, R. C, & Askanas, V. DiMauro S, Engel A, Karpati G, Mendell JR, et al. Inclusion body myositis and myopathies. Annals of neurology (1995). , 38(5), 705-713.

[25] Amato, A. A, Gronseth, G. S, Jackson, C. E, Wolfe, G. I, Katz, J. S, Bryan, W. W, et al. Inclusion body myositis: clinical and pathological boundaries. Annals of neurology (1996). , 40(4), 581-586.

[26] Askanas, V, Engel, W. K, & Nogalska, A. Pathogenic considerations in sporadic inclusion-body myositis, a degenerative muscle disease associated with aging and abnormalities of myoproteostasis. Journal of neuropathology and experimental neurology (2012). , 71(8), 680-693.

[27] Askanas, V, & Engel, W. K. Inclusion-body myositis: muscle-fiber molecular pathology and possible pathogenic significance of its similarity to Alzheimer's and Parkinson's disease brains. Acta neuropathologica (2008). , 116(6), 583-595.

[28] Askanas, V, & Engel, W. K. Inclusion-body myositis: a myodegenerative conformational disorder associated with Abeta, protein misfolding, and proteasome inhibition. Neurology (2006). Suppl 1) S, 39-48.

[29] Hayashi, Y. K. Myofibrillar myopathy]. Brain and nerve = Shinkei kenkyu no shinpo (2011). , 63(11), 1179-1188.

[30] Selcen, D. Myofibrillar myopathies. Neuromuscular disorders : NMD (2011). , 21(3), 161-171.

[31] Selcen, D, Ohno, K, & Engel, A. G. Myofibrillar myopathy: clinical, morphological and genetic studies in 63 patients. Brain : a journal of neurology (2004). Pt 2) 439-451.

[32] Tannous, P, Zhu, H, Johnstone, J. L, Shelton, J. M, Rajasekaran, N. S, Benjamin, I. J, et al. Autophagy is an adaptive response in desmin-related cardiomyopathy. Proceedings of the National Academy of Sciences of the United States of America (2008). , 105(28), 9745-9750.

[33] Watts, G. D, Wymer, J, Kovach, M. J, Mehta, S. G, Mumm, S, Darvish, D, et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal de-

mentia is caused by mutant valosin-containing protein. Nature genetics (2004). , 36(4), 377-381.

[34] Weihl, C. C, Pestronk, A, & Kimonis, V. E. Valosin-containing protein disease: inclusion body myopathy with Paget's disease of the bone and fronto-temporal dementia. Neuromuscular disorders : NMD (2009). , 19(5), 308-315.

[35] Kimonis, V. E, & Watts, G. D. Autosomal dominant inclusion body myopathy, Paget disease of bone, and frontotemporal dementia. Alzheimer disease and associated disorders (2005). Suppl 1 S, 44-47.

[36] Guyant-marechal, L, Laquerriere, A, Duyckaerts, C, Dumanchin, C, Bou, J, Dugny, F, et al. Valosin-containing protein gene mutations: clinical and neuropathologic features. Neurology (2006). , 67(4), 644-651.

[37] Tresse, E, Salomons, F. A, Vesa, J, Bott, L. C, Kimonis, V, Yao, T. P, et al. VCP/97 is essential for maturation of ubiquitin-containing autophagosomes and this function is impaired by mutations that cause IBMPFD. Autophagy (2010).

[38] Sjogren, T. Hereditary congenital spinocerebellar ataxia accompanied by congenital cataract and oligophrenia; a genetic and clinical investigation. Confinia neurologica (1950). , 10(5), 293-308.

[39] Goto, Y, Komiyama, A, Tanabe, Y, Katafuchi, Y, Ohtaki, E, & Nonaka, I. Myopathy in Marinesco-Sjogren syndrome: an ultrastructural study. Acta neuropathologica (1990). , 80(2), 123-128.

[40] Zhao, L, Rosales, C, Seburn, K, Ron, D, & Ackerman, S. L. Alteration of the unfolded protein response modifies neurodegeneration in a mouse model of Marinesco-Sjogren syndrome. Human molecular genetics (2010). , 19(1), 25-35.

[41] Brais, B, Bouchard, J. P, Xie, Y. G, Rochefort, D. L, Chretien, N, Tome, F. M, et al. Short GCG expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy. Nature genetics (1998). , 18(2), 164-167.

[42] La Spada AR, Taylor JP.Repeat expansion disease: progress and puzzles in disease pathogenesis. Nature reviews Genetics (2010). , 11(4), 247-258.

[43] Nonaka, I, Sunohara, N, Ishiura, S, & Satoyoshi, E. Familial distal myopathy with rimmed vacuole and lamellar (myeloid) body formation. Journal of the neurological sciences (1981). , 51(1), 141-155.

[44] Nonaka, I, Murakami, N, Suzuki, Y, & Kawai, M. Distal myopathy with rimmed vacuoles. Neuromuscular disorders : NMD (1998). , 8(5), 333-337.

[45] Argov, Z, & Yarom, R. Rimmed vacuole myopathy" sparing the quadriceps. A unique disorder in Iranian Jews. Journal of the neurological sciences (1984). , 64(1), 33-43.

[46] Nishino, I, Noguchi, S, Murayama, K, Driss, A, Sugie, K, Oya, Y, et al. Distal myopathy with rimmed vacuoles is allelic to hereditary inclusion body myopathy. Neurology (2002). , 59(11), 1689-1693.

[47] Malicdan, M. C, Noguchi, S, Nonaka, I, Hayashi, Y. K, & Nishino, I. A Gne knockout mouse expressing human GNE D176V mutation develops features similar to distal myopathy with rimmed vacuoles or hereditary inclusion body myopathy. Human molecular genetics (2007). , 16(22), 2669-2682.

[48] Mori-yoshimura, M, Monma, K, Suzuki, N, Aoki, M, Kumamoto, T, Tanaka, K, et al. Heterozygous UDP-GlcNAc epimerase and N-acetylmannosamine kinase domain mutations in the GNE gene result in a less severe GNE myopathy phenotype compared to homozygous N-acetylmannosamine kinase domain mutations. Journal of the neurological sciences (2012). , 2.

[49] Nonaka, I, Noguchi, S, & Nishino, I. Distal myopathy with rimmed vacuoles and hereditary inclusion body myopathy. Current neurology and neuroscience reports (2005). , 5(1), 61-65.

[50] Eisenberg, I, Avidan, N, Potikha, T, Hochner, H, Chen, M, Olender, T, et al. The UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase gene is mutated in recessive hereditary inclusion body myopathy. Nature genetics (2001). , 29(1), 83-87.

[51] Arai, A, Tanaka, K, Ikeuchi, T, Igarashi, S, Kobayashi, H, Asaka, T, et al. A novel mutation in the GNE gene and a linkage disequilibrium in Japanese pedigrees. Annals of neurology (2002). , 52(4), 516-519.

[52] Tomimitsu, H, Shimizu, J, Ishikawa, K, Ohkoshi, N, Kanazawa, I, & Mizusawa, H. Distal myopathy with rimmed vacuoles (DMRV): new GNE mutations and splice variant. Neurology (2004). , 62(9), 1607-1610.

[53] Broccolini, A, Ricci, E, Cassandrini, D, Gliubizzi, C, Bruno, C, Tonoli, E, et al. Novel GNE mutations in Italian families with autosomal recessive hereditary inclusion-body myopathy. Human mutation (2004).

[54] Kim, B. J, Ki, C. S, Kim, J. W, Sung, D. H, Choi, Y. C, & Kim, S. H. Mutation analysis of the GNE gene in Korean patients with distal myopathy with rimmed vacuoles. Journal of human genetics (2006). , 51(2), 137-140.

[55] Liewluck, T, Pho-iam, T, Limwongse, C, Thongnoppakhun, W, Boonyapisit, K, Raksadawan, N, et al. Mutation analysis of the GNE gene in distal myopathy with rimmed vacuoles (DMRV) patients in Thailand. Muscle & nerve (2006). , 34(6), 775-778.

[56] Li, H, Chen, Q, Liu, F, Zhang, X, Liu, T, Li, W, et al. Clinical and molecular genetic analysis in Chinese patients with distal myopathy with rimmed vacuoles. Journal of human genetics (2011). , 56(4), 335-338.

[57] Noguchi, S, Keira, Y, Murayama, K, Ogawa, M, Fujita, M, Kawahara, G, et al. Reduction of UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase activity

and sialylation in distal myopathy with rimmed vacuoles. The Journal of biological chemistry (2004). , 279(12), 11402-11407.

[58] Schwarzkopf, M, Knobeloch, K. P, Rohde, E, Hinderlich, S, Wiechens, N, Lucka, L, et al. Sialylation is essential for early development in mice. Proceedings of the National Academy of Sciences of the United States of America (2002). , 99(8), 5267-5270.

[59] Malicdan, M. C, Noguchi, S, & Nishino, I. A preclinical trial of sialic acid metabolites on distal myopathy with rimmed vacuoles/hereditary inclusion body myopathy, a sugar-deficient myopathy: a review. Therapeutic advances in neurological disorders (2010). , 3(2), 127-135.

[60] Malicdan, M. C, Noguchi, S, Hayashi, Y. K, & Nishino, I. Muscle weakness correlates with muscle atrophy and precedes the development of inclusion body or rimmed vacuoles in the mouse model of DMRV/hIBM. Physiological genomics (2008). , 35(1), 106-115.

[61] Malicdan, M. C, Noguchi, S, & Nishino, I. Autophagy in a mouse model of distal myopathy with rimmed vacuoles or hereditary inclusion body myopathy. Autophagy (2007). , 3(4), 396-398.

[62] Malicdan, M. C, Noguchi, S, Hayashi, Y. K, Nonaka, I, & Nishino, I. Prophylactic treatment with sialic acid metabolites precludes the development of the myopathic phenotype in the DMRV-hIBM mouse model. Nature medicine (2009). , 15(6), 690-695.

[63] Mizushima, N, & Komatsu, M. Autophagy: renovation of cells and tissues. Cell (2011). , 147(4), 728-741.

[64] Yu, W. H, Cuervo, A. M, Kumar, A, Peterhoff, C. M, Schmidt, S. D, Lee, J. H, et al. Macroautophagy--a novel Beta-amyloid peptide-generating pathway activated in Alzheimer's disease. The Journal of cell biology (2005). , 171(1), 87-98.

[65] Scherz-shouval, R, Shvets, E, Fass, E, Shorer, H, Gil, L, & Elazar, Z. Reactive oxygen species are essential for autophagy and specifically regulate the activity of Atg4. The EMBO journal (2007). , 26(7), 1749-1760.

[66] Iijima, R, Takahashi, H, Namme, R, Ikegami, S, & Yamazaki, M. Novel biological function of sialic acid (N-acetylneuraminic acid) as a hydrogen peroxide scavenger. FEBS letters (2004).